Clinical outcomes of type III Pseudomonas aeruginosa bacteremia*
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Pseudomonas aeruginosa bacteremia is a serious and life-threatening infection associated with high mortality. Among the multitude of virulence determinants possessed by P. aeruginosa, the type 3 secretion system has been implicated with more acute and invasive infection in respiratory diseases. However, the relationship between the type 3 secretion system and clinical outcomes in P. aeruginosa bacteremia has not been investigated. OBJECTIVES: To determine the association between the type 3 secretion system virulence factor in P. aeruginosa bloodstream infection and 30-day mortality. DESIGN: Retrospective analysis of 85 cases of P. aeruginosa bacteremia. SETTING: Tertiary care hospital. INTERVENTIONS: Bacterial isolates were assayed in vitro for secretion of type 3 exotoxins (ExoU, ExoT, and ExoS). Strain relatedness was analyzed using randomly amplified polymorphic DNA polymerase chain reaction genotyping. Antimicrobial susceptibilities were determined by means of the Kirby-Bauer disk-diffusion test. MEASUREMENTS AND MAIN RESULTS: At least one of the type 3 secretion system proteins was detected in 37 out of the 85 isolates (44%). Septic shock was identified in 43% of bacteremic patients with type 3 secretion system+ isolates compared to 23% of patients with type 3 secretion system- isolates (p = .12). A high frequency of resistance in the type 3 secretion system+ isolates was observed to ciprofloxacin (59%), cefepime (35%), and gentamicin (38%). There was a significant difference in the 30-day cumulative probability of death after bacteremia between secretors and nonsecretors (p = .02). None of the type 3 secretion system+ patients who survived the first 30 days had a P. aeruginosa isolate which exhibited ExoU phenotype. CONCLUSIONS: The expression of type 3 secretion system exotoxins in bacteremic isolates of P. aeruginosa confers poor clinical outcomes independent of antibiotic susceptibility profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 5×
“(1) (n 5 37) Type III Secretion System”
BackgroundInfluential
Cited by
Horcajada, J. P., Montero, M., Oliver, A., Sorlí, L., Luque, S., Gómez-Zorrilla, S., Benito, N., & Grau, S. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00031-19 · Cited by 961
ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics
Miller, W. R., & Arias, C. A. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-024-01054-w · Cited by 862
Kadri, S. S., Lai, Y. L., Warner, S., Strich, J. R., Babiker, A., Ricotta, E. E., Demirkale, C. Y., Dekker, J. P., Palmore, T. N., Rhee, C., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30477-1 · Cited by 279
Pathogenesis of Gram-Negative Bacteremia
Holmes, C. L., Anderson, M. T., Mobley, H. L. T., & Bachman, M. A. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00234-20 · Cited by 277
Bacterial Sphingomyelinases and Phospholipases as Virulence Factors
Flores-Díaz, M., Monturiol-Gross, L., Naylor, C., Alape-Girón, A., & Flieger, A. (2016) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00082-15 · Cited by 207
“Furthermore, ExoU constitutes a virulence marker, since ExoU-expressing strains are significantly associated with bacteremia, more severe disease, higher complication rates, and greater mortality in pneumonia patients (132, 163).”
Background
Metadata
- Authors
- El-Solh, A. A., Hattemer, A., Hauser, A. R., Alhajhusain, A., & Vora, H.
- Venue
- Critical Care Medicine
- Published
- 2012-04
- Volume
- 40
- Issue
- 4
- Pages
- 1157-1163
- ISSN
- 0090-3493 (ISSN-L)
- OpenAlex
- W1978839325
- Cited by
- 120
- References
- 1
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.